Enzyme Replacement Therapy Market Outlook:
Enzyme Replacement Therapy Market size was valued at USD 12.74 billion in 2025 and is likely to cross USD 29.61 billion by 2035, registering more than 8.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of enzyme replacement therapy is assessed at USD 13.75 billion.
The growth of the market can be attributed to rising prevalence of lysosomal storage diseases (LSDs) in the population owing to rising diseases and an unhealthy lifestyle. There were 766 LSD diagnoses in the Australian population during the 12-year period, January 2009 through December 2020, including 32 successful pregnancies.
Also, the growing population is expected to boost the market further over the forecast period. The growth in population is anticipated to lead a rise in the prevalence of rare diseases, which is also expected to fuel the demand for enzyme replacement therapy. The population of the world is projected to rise by 2 billion people during the next 30 years, from 7.7 billion people today to 9.7 billion in 2050, with a potential peak of approximately 11 billion people around the year 2100.
The worldwide incidence of lysosomal storage illnesses, including Gaucher, Fabry, Pompe, and MPS, is steadily rising. For instance, as per information released by the National Institute of Neurological Disorders and Stroke in August 2021, approximately one in 40,000 individuals in the United States had Pompe disease, which is predicted to be roughly 32,950 individuals. Furthermore, the National Fabry Foundation estimates that the entire Fabry patient number in the USA will be roughly 7,713 in May 2020. As a result of the significant number of patients experiencing rare lysosomal storage illnesses, there is a huge requirement for efficient treatments, including enzyme replacement therapy.
